000862515 001__ 862515
000862515 005__ 20210130001428.0
000862515 0247_ $$2doi$$a10.1097/WCO.0000000000000701
000862515 0247_ $$2ISSN$$a1350-7540
000862515 0247_ $$2ISSN$$a1473-6551
000862515 0247_ $$2altmetric$$aaltmetric:59031670
000862515 0247_ $$2pmid$$apmid:30985373
000862515 0247_ $$2WOS$$aWOS:000480723400001
000862515 037__ $$aFZJ-2019-02818
000862515 082__ $$a610
000862515 1001_ $$0P:(DE-HGF)0$$aSchweitzer, Finja$$b0
000862515 245__ $$aAge and the risks of high-efficacy disease modifying drugs in multiple sclerosis
000862515 260__ $$a[S.l.]$$bOvid$$c2019
000862515 3367_ $$2DRIVER$$aarticle
000862515 3367_ $$2DataCite$$aOutput Types/Journal article
000862515 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1556612680_29429
000862515 3367_ $$2BibTeX$$aARTICLE
000862515 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000862515 3367_ $$00$$2EndNote$$aJournal Article
000862515 520__ $$aA variety of high-efficacy disease-modifying therapies (DMTs) are available for the treatment of multiple sclerosis (MS). After evaluation and approval by regulatory agencies, DMTs are likely to be administered to patients whose characteristics differ from those enrolled in clinical trials. This may contribute to the emergence of unexpected adverse events observed in the real-world setting. Higher age may be a relevant factor that could change the benefit–risk balance of DMTs, as it may associate with lower efficiency and higher frequency of adverse events.
000862515 536__ $$0G:(DE-HGF)POF3-572$$a572 - (Dys-)function and Plasticity (POF3-572)$$cPOF3-572$$fPOF III$$x0
000862515 588__ $$aDataset connected to CrossRef
000862515 7001_ $$0P:(DE-HGF)0$$aLaurent, Sarah$$b1
000862515 7001_ $$0P:(DE-Juel1)131720$$aFink, Gereon Rudolf$$b2
000862515 7001_ $$0P:(DE-HGF)0$$aBarnett, Michael H.$$b3
000862515 7001_ $$0P:(DE-HGF)0$$aReddel, Stephen$$b4
000862515 7001_ $$0P:(DE-HGF)0$$aHartung, Hans-Peter$$b5
000862515 7001_ $$0P:(DE-HGF)0$$aWarnke, Clemens$$b6$$eCorresponding author
000862515 773__ $$0PERI:(DE-600)2026967-5$$a10.1097/WCO.0000000000000701$$gVol. 32, no. 3, p. 305 - 312$$n3$$p305 - 312$$tCurrent opinion in neurology$$v32$$x1350-7540$$y2019
000862515 909CO $$ooai:juser.fz-juelich.de:862515$$pVDB
000862515 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)131720$$aForschungszentrum Jülich$$b2$$kFZJ
000862515 9131_ $$0G:(DE-HGF)POF3-572$$1G:(DE-HGF)POF3-570$$2G:(DE-HGF)POF3-500$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bKey Technologies$$lDecoding the Human Brain$$v(Dys-)function and Plasticity$$x0
000862515 9141_ $$y2019
000862515 915__ $$0StatID:(DE-HGF)0410$$2StatID$$aAllianz-Lizenz
000862515 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz
000862515 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bCURR OPIN NEUROL : 2017
000862515 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000862515 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000862515 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000862515 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List
000862515 915__ $$0StatID:(DE-HGF)0110$$2StatID$$aWoS$$bScience Citation Index
000862515 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000862515 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000862515 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine
000862515 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews
000862515 915__ $$0StatID:(DE-HGF)1120$$2StatID$$aDBCoverage$$bBIOSIS Reviews Reports And Meetings
000862515 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5
000862515 920__ $$lyes
000862515 9201_ $$0I:(DE-Juel1)INM-3-20090406$$kINM-3$$lKognitive Neurowissenschaften$$x0
000862515 980__ $$ajournal
000862515 980__ $$aVDB
000862515 980__ $$aI:(DE-Juel1)INM-3-20090406
000862515 980__ $$aUNRESTRICTED